RET and thyroid gland carcinoma: Applying targeted NGS of 57 thyroid-cancer-related genes demonstrates the expected mutations in BRAF and RET. In our cohort, BRAF mutation is the most prevalent alternation, aligned with many landmark researches (9, 23, 24).